Steven Cohen Bicycle Therapeutics PLC Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 4,554,900 shares of BCYC stock, worth $57.2 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
4,554,900
Previous 899,799
406.21%
Holding current value
$57.2 Million
Previous $20.4 Million
212.48%
% of portfolio
0.15%
Previous 0.06%
Shares
20 transactions
Others Institutions Holding BCYC
# of Institutions
106Shares Held
40.6MCall Options Held
19.6KPut Options Held
16.9K-
Baker Bros. Advisors LP New York, NY10.9MShares$137 Million1.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$43.3 Million8.16% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.61MShares$32.8 Million0.17% of portfolio
-
Armistice Capital, LLC New York, NY2.2MShares$27.6 Million0.43% of portfolio
-
Siren, L.L.C. New York, NY1.84MShares$23.1 Million1.14% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $372M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...